Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. The company is headquartered in Palo Alto, California and currently employs 12 full-time employees. The company went IPO on 2020-03-10. The firm is focused on developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. The company has a next generation bioconjugation platform, called VersAptx. Its product candidates include VIP943 (CD123-KSPi), VIP924 (CXCR5-KSPi), VIP236, and Enitociclib (positive transcription elongation factor beta (P-TEFb)/CDK9 inhibitor). Its VIP943 is developed using its VersAptx platform and combines an anti-CD123 antibody, a novel legumain-cleavable linker and a kinesin spindle protein inhibitor payload enhanced with CellTrapper technology. Enitociclib is a selective CDK9 inhibitor. Enitociclib effectively blocks P-TEFb-mediated activation of RNA polymerase II, preventing transcription of MCL1 and MYC, proteins associated with poor prognosis in various types of cancer.
Follow-Up Questions
VINC hissesinin fiyat performansı nasıl?
VINC 'in mevcut fiyatı $0.04 'dir, son işlem günde 0% decreased etti.
Vincerx Pharma Inc için ana iş temaları veya sektörler nelerdir?
Vincerx Pharma Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
Vincerx Pharma Inc 'in piyasa değerlemesi nedir?
Vincerx Pharma Inc 'in mevcut piyasa değerlemesi $209.2K 'dir
Vincerx Pharma Inc al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 3 analist Vincerx Pharma Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 2 güçlü al, 4 al, 1 tut, 0 sat ve 2 güçlü sat içermektedir
